Muhammad Waqas1, Kunal Vakhari1, Peter V Weimer2, Eisa Hashmi2, Jason M Davies3, Adnan H Siddiqui4. 1. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA. 2. Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA. 3. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Department of Bioinformatics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Canon Stroke and Vascular Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA; Jacobs Institute, Buffalo, New York, USA. 4. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Department of Radiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Canon Stroke and Vascular Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA; Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, New York, USA; Jacobs Institute, Buffalo, New York, USA. Electronic address: asiddiqui@ubns.com.
Abstract
INTRODUCTION: Embolization of the middle meningeal artery (MMA) has emerged as a minimally invasive means of managing subdural hematoma. The purpose of this study was to systematically review the literature on the safety and effectiveness of this treatment and to share our clinical experience. METHODS: This review was registered with PROSPERO. PubMed, CINAHL, EMBASE, and the Cochrane Library were searched using MeSH (Medical Subject Headings) terms for MMA embolization and chronic subdural hematoma (CSDH) from January 2000 to November 2018. All articles in the English language literature describing MMA embolization for CSDH were included, irrespective of study design. Consecutive patients who underwent MMA embolization at our hospital between January 2017 and June 2018 comprised our clinical experience. RESULTS: Fifteen studies with 193 procedures were included in the review. Ninety-five cases (49.2%) involved primary MMA embolization; 88 embolizations (45.6%) for recurrent CSDH and 10 (5.2%) for prophylaxis after surgical evacuation were performed. Recurrence after MMA embolization requiring further treatment occurred in 7 cases (3.6%). All other patients had symptomatic relief with no further recurrence. No procedure-related complications were reported. Polyvinyl alcohol was the most commonly used material. Our series included 8 patients treated with Onyx. All had symptom relief and significant reduction in hematoma size; no recurrences or procedure-related complications were observed. CONCLUSIONS: MMA embolization of CSDH is safe and effective for CSDH treatment based on a documented recurrence rate of 3.6% and lack of reported complications.
INTRODUCTION: Embolization of the middle meningeal artery (MMA) has emerged as a minimally invasive means of managing subdural hematoma. The purpose of this study was to systematically review the literature on the safety and effectiveness of this treatment and to share our clinical experience. METHODS: This review was registered with PROSPERO. PubMed, CINAHL, EMBASE, and the Cochrane Library were searched using MeSH (Medical Subject Headings) terms for MMA embolization and chronic subdural hematoma (CSDH) from January 2000 to November 2018. All articles in the English language literature describing MMA embolization for CSDH were included, irrespective of study design. Consecutive patients who underwent MMA embolization at our hospital between January 2017 and June 2018 comprised our clinical experience. RESULTS: Fifteen studies with 193 procedures were included in the review. Ninety-five cases (49.2%) involved primary MMA embolization; 88 embolizations (45.6%) for recurrent CSDH and 10 (5.2%) for prophylaxis after surgical evacuation were performed. Recurrence after MMA embolization requiring further treatment occurred in 7 cases (3.6%). All other patients had symptomatic relief with no further recurrence. No procedure-related complications were reported. Polyvinyl alcohol was the most commonly used material. Our series included 8 patients treated with Onyx. All had symptom relief and significant reduction in hematoma size; no recurrences or procedure-related complications were observed. CONCLUSIONS:MMA embolization of CSDH is safe and effective for CSDH treatment based on a documented recurrence rate of 3.6% and lack of reported complications.
Authors: F Al-Mufti; G Kaur; K Amuluru; J B Cooper; K Dakay; M El-Ghanem; J Pisapia; C Muh; R Tyagi; C Bowers; C Cole; S Rosner; J Santarelli; S Mayer; C Gandhi Journal: AJNR Am J Neuroradiol Date: 2021-03-04 Impact factor: 3.825
Authors: Ahmed Helal; Kunal Vakharia; Waleed Brinjikji; Matthew L Carlson; Colin Lw Driscoll; Jamie J Van Gompel; Michael J Link; Harry Cloft Journal: Interv Neuroradiol Date: 2021-05-26 Impact factor: 1.764
Authors: Andrea Di Cristofori; Paolo Remida; Mirko Patassini; Lorenzo Piergallini; Raffaella Buonanno; Raffaele Bruno; Giorgio Carrabba; Giacomo Pavesi; Corrado Iaccarino; Carlo Giorgio Giussani Journal: Surg Neurol Int Date: 2022-03-18
Authors: Joshua S Catapano; Candice L Nguyen; Andre A Wakim; Felipe C Albuquerque; Andrew F Ducruet Journal: Front Neurol Date: 2020-10-20 Impact factor: 4.003
Authors: Helen C U Ota; Brandon G Smith; Alexander Alamri; Faith C Robertson; Hani Marcus; Allison Hirst; Marike Broekman; Peter Hutchinson; Peter McCulloch; Angelos Kolias Journal: Acta Neurochir (Wien) Date: 2020-07-10 Impact factor: 2.216